Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women
Tóm tắt
The identification of variants in the nicotinic acetylcholine receptor (nAChR) subunit genes associated with smoking phenotypes are increasingly important for prevention and treatment of nicotine dependence. In the context of personalized medicine, the aims of this study were to evaluate whether cholinergic receptor nicotinic alpha 2 (CHRNA2), cholinergic receptor nicotinic alpha 3 (CHRNA3), cholinergic receptor nicotinic alpha 5 (CHRNA5) and cholinergic receptor nicotinic beta 3 (CHRNB3) polymorphisms were associated with nicotine dependence severity, and to investigate possible pharmacogenetics markers of smoking cessation treatment. This study cohort enrolled 1049 smoking patients who received pharmacological treatment (varenicline, varenicline plus bupropion, bupropion plus/or nicotine replacement therapy). Smoking cessation success was considered for patients who completed 6 months of continuous abstinence. Fagerström test for nicotine dependence (FTND) and Issa situational smoking scores (Issa score) were analyzed for nicotine dependence. CHRNA2 (rs2472553), CHRNA3 (rs1051730), CHRNA5 (rs16969968 and rs2036527) and CHRNB3 (rs6474413) polymorphisms were genotyped by high resolution melting analysis. Females with GA and AA genotypes for CHRNA5 rs16969968 and rs2036527 polymorphisms had higher success rate in smoking cessation treatment: 44.0% and 56.3% (rs16969968), 41.5% and 56.5% (rs2036527), respectively, compared with carriers of the GG genotypes: 35.7% (rs16969968), 34.8% (rs2036527), (P = 0.03, n = 389; P = 0.01, n = 391). The GA or AA genotypes for the rs16969968 and rs2036527 were associated with higher odds ratio for success in women (OR = 1.63; 95% CI = 1.04 to 2.54; P = 0.03 and OR = 1.59, 95% CI = 1.02 to 2.48; P = 0.04; respectively). We did not find association of these polymorphisms with nicotine dependence related scores. Polymorphisms in the CHRNA2, CHRNA3 and CHRNB3 genes were not associated with the phenotypes studied. CHRNA5 rs16969968 and rs2036527 were associated with higher success rate in the smoking cessation treatment in women. These findings might contribute to advances in personalized medicine.
Tài liệu tham khảo
Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau O, et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum Mol Genet. 2007;16(1):36–49.
Sarginson JE, Killen JD, Lazzeroni LC, Fortmann SP, Ryan HS, Schatzberg AF, Murphy GM Jr. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):275–84.
Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J. 1998;53(suppl):75–114.
Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci. 2004;5(1):55–65.
Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Clinical Practice Guideline. Respir Care. 2000;45(10):1196–9.
Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville: U.S. Department of Health and Human Services. Public Health Service;2008.
Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295(1):321–7.
Sieminska A, Jassem E, Kita-Milczarska K. Nicotine dependence in an isolated population of Kashubians from North Poland: a population survey. BMC Public Health. 2015;15:80.
Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7(2):81–98.
Hiroi N, Scott D. Constitutional mechanisms of vulnerability and resilience to nicotine dependence. Mol Psychiatry. 2009;14(7):653–67.
Dash B, Lukas RJ, Li MD. A signal peptide missense mutation associated with nicotine dependence alters alpha2*-nicotinic acetylcholine receptor function. Neuropharmacology. 2014;79:715–25.
Culverhouse RC, Johnson EO, Breslau N, Hatsukami DK, Sadler B, Brooks AI, Hesselbrock VM, Schuckit MA, Tischfield JA, Goate AM, et al. Multiple distinct CHRNB3-CHRNA6 variants are genetic risk factors for nicotine dependence in African Americans and European Americans. Addiction. 2014;109(5):814–22.
Wang S, DvdV A, Xu Q, Seneviratne C, Pomerleau OF, Pomerleau CS, Payne TJ, Ma JZ, Li MD. Significant associations of CHRNA2 and CHRNA6 with nicotine dependence in European American and African American populations. Hum Genet. 2014;133(5):575–86.
Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X, Saccone NL, Saccone SF, Bertelsen S, Fox L, et al. Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry. 2008;165(9):1163–71.
Caporaso N, Gu F, Chatterjee N, Sheng-Chih J, Yu K, Yeager M, Chen C, Jacobs K, Wheeler W, Landi MT, et al. Genome-wide and candidate gene association study of cigarette smoking behaviors. PLoS One. 2009;4(2):e4653.
Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL, Thun MJ, Goate A, Calle EE. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomark Prev. 2008;17(12):3517–25.
Issa JS, Abe TO, Moura S, Santos PC, Pereira AC. Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nicotine Tob Res. 2013;15(6):1146–50.
Issa JS, Santos PC, Vieira LP, Abe TO, Kuperszmidt CS, Nakasato M, Cardoso E, Amorim C, Pereira AC. Smoking cessation and weight gain in patients with cardiovascular disease or risk factor. Int J Cardiol. 2014;172(2):485–7.
Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J. 1990;69(11):763–5.
Issa JS. A new nicotine dependence score and a new scale assessing patient comfort during smoking cessation treatment. J Bras Pneumol. 2012;38(6):761–5.
Santos PC, Soares RA, Nascimento RM, Machado-Coelho GL, Mill JG, Krieger JE, Pereira AC. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet. 2011;12:136.
Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, Mill JG, Krieger JE, Pereira AC. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011;12:13.
The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42(5):441–7.
Chen LS, Hung RJ, Baker T, Horton A, Culverhouse R, Saccone N, Cheng I, Deng B, Han Y, Hansen HM, et al. CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis. J Natl Cancer Inst. 2015;107(5)
Bandiera FC, Ross KC, Taghavi S, Delucchi K, Tyndale RF, Benowitz NL. Nicotine dependence, nicotine metabolism, and the extent of compensation in response to reduced nicotine content cigarettes. Nicotine Tob Res. 2015;17(9):1167–72.
Hubacek JA, Lanska V, Adamkova V. Lack of an association between SNPs within the cholinergic receptor genes and smoking behavior in a Czech post-MONICA study. Genet Mol Biol. 2014;37(4):625–30.
Broms U, Wedenoja J, Largeau MR, Korhonen T, Pitkaniemi J, Keskitalo-Vuokko K, Happola A, Heikkila KH, Heikkila K, Ripatti S, et al. Analysis of detailed phenotype profiles reveals CHRNA5-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits. Nicotine Tob Res. 2012;14(6):720–33.
Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, OF P, Swan GE, Rutter J, Bertelsen S, Fox L, et al. Novel genes identified in a high-density genome wide association study for nicotine dependence. Hum Mol Genet. 2007;16(1):24–35.
Baker TB, Weiss RB, Bolt D, von Niederhausern A, Fiore MC, Dunn DM, Piper ME, Matsunami N, Smith SS, Coon H, et al. Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes. Nicotine Tob Res. 2009;11(7):785–96.
Freathy RM, Ring SM, Shields B, Galobardes B, Knight B, Weedon MN, Smith GD, Frayling TM, Hattersley AT. A common genetic variant in the 15q24 nicotinic acetylcholine receptor gene cluster (CHRNA5-CHRNA3-CHRNB4) is associated with a reduced ability of women to quit smoking in pregnancy. Hum Mol Genet. 2009;18(15):2922–7.
King DP, Paciga S, Pickering E, Benowitz NL, Bierut LJ, Conti DV, Kaprio J, Lerman C, Park PW. Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacology. 2012;37(3):641–50.
Rocha Santos J, Tomaz PR, Issa JS, TO A, Krieger JE, Pereira AC, Santos PC. CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. Front Genet. 2015;6:46.
Tomaz PR, Santos JR, Issa JS, TO A, Gaya PV, Krieger JE, Pereira AC, Santos PC. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Eur J Clin Pharmacol. 2015;71(9):1067–73.
Kuryatov A, Berrettini W, Lindstrom J. Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)(2)alpha5 AChR function. Mol Pharmacol. 2011;79(1):119–25.
Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics. 2013;23(2):94–103.
Chen LS, Baker TB, Jorenby D, Piper M, Saccone N, Johnson E, Breslau N, Hatsukami D, Carney RM, Bierut LJ. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend. 2015;154:278–82.
Jensen KP, DeVito EE, Herman AI, Valentine GW, Gelernter J, Sofuoglu M. A CHRNA5 smoking risk variant decreases the aversive effects of nicotine in humans. Neuropsychopharmacology. 2015;40(12):2813–21.
Zawertailo L, Voci S, Selby P. Depression status as a predictor of quit success in a real-world effectiveness study of nicotine replacement therapy. Psychiatry Res. 2015;226(1):120–7.
Goodwin RD, Wall MM, Choo T, Galea S, Horowitz J, Nomura Y, Zvolensky MJ, Hasin DS. Changes in the prevalence of mood and anxiety disorders among male and female current smokers in the United States: 1990-2001. Ann Epidemiol. 2014;24(7):493–7.
Stepankova L, Kralikova E, Zvolska K, Kmetova A, Blaha M, Bortlicek Z, Sticha M, Anders M, Schroeder DR, Croghan IT. Tobacco treatment outcomes in patients with and without a history of depression, Czech Republic, 2005-2010. Prev Chronic Dis. 2013;10:E158.
Scott WD, Beevers CG, Mermelstein RJ. Depression vulnerable and nonvulnerable smokers after a failure experience: examining cognitive self-regulation and motivation. Behav Modif. 2008;32(4):519–39.
Covey LS, Glassman AH, Stetner F. Depression and depressive symptoms in smoking cessation. Compr Psychiatry. 1990;31(4):350–4.
Beltz AM, Berenbaum SA, Wilson SJ. Sex differences in resting state brain function of cigarette smokers and links to nicotine dependence. Exp Clin Psychopharmacol. 2015;23(4):247–54.
Smith PH, Kasza KA, Hyland A, Fong GT, Borland R, Brady K, Carpenter MJ, Hartwell K, Cummings KM, McKee SA. Gender differences in medication use and cigarette smoking cessation: results from the international tobacco control four country survey. Nicotine Tob Res. 2015;17(4):463–72.
Pierce JP, Lee L, Gilpin EA. Smoking initiation by adolescent girls, 1944 through 1988. An association with targeted advertising. JAMA. 1994;271(8):608–11.
Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: a review. Prev Med. 2016;92:135–40.
Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, Gray KM, Mazure CM, Wetherington CL, McKee SA. Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. Nicotine Tob Res. 2015;17(4):407–21.
McVay MA, Copeland AL. Smoking cessation in peri- and postmenopausal women: a review. Exp Clin Psychopharmacol. 2011;19(3):192–202.
Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res. 2008;10(7):1245–50.
De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, Salhi B, Van Meerbeeck J, Thierens H. Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010;11(8):1053–63.
Munafo MR, Johnstone EC, Walther D, Uhl GR, Murphy MF, Aveyard P. CHRNA3 rs1051730 genotype and short-term smoking cessation. Nicotine Tob Res. 2011;13(10):982–8.
Kim DK, Hersh CP, Washko GR, Hokanson JE, Lynch DA, Newell JD, Murphy JR, Crapo JD, Silverman EK. Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res. 2011;12:9.
Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CHRNA3 genotype, nicotine dependence, lung function and disease in the general population. Eur Respir J. 2012;40(6):1538–44.
Petrovsky N, Ettinger U, Kessler H, Mossner R, Wolfsgruber S, Dahmen N, Maier W, Wagner M, Quednow BB. The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. Psychopharmacology. 2016;229(1):31–40.
Wen L, Jiang K, Yuan W, Cui W, Li MD. Contribution of variants in CHRNA5/A3/B4 gene cluster on chromosome 15 to tobacco smoking: from genetic association to mechanism. Mol Neurobiol. 2016;53(1):472–84.
Buczkowski K, Sieminska A, Linkowska K, Czachowski S, Przybylski G, Jassem E, Grzybowski T. Association between genetic variants on chromosome 15q25 locus and several nicotine dependence traits in polish population: a case-control study. Biomed Res Int. 2015;2015:350348.
Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103(17):1342–6.
Robinson JD, Versace F, Lam CY, Minnix JA, Engelmann JM, Cui Y, Karam-Hage M, Shete SS, Tomlinson GE, Chen TT, et al. The CHRNA3 rs578776 variant is associated with an intrinsic reward sensitivity deficit in smokers. Front Psychiatry. 2013;4:114.
Erlich PM, Hoffman SN, Rukstalis M, Han JJ, Chu X, Linda Kao WH, Gerhard GS, Stewart WF, Boscarino JA. Nicotinic acetylcholine receptor genes on chromosome 15q25.1 are associated with nicotine and opioid dependence severity. Hum Genet. 2010;128(5):491–9.
Verde Z, Santiago C, Rodriguez Gonzalez-Moro JM, de Lucas Ramos P, Lopez Martin S, Bandres F, Lucia A, Gomez-Gallego F. 'Smoking genes': a genetic association study. PLoS One. 2011;6(10):e26668.
Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H, Lu EY, Scheet P, Greisinger AJ, Mills GB, Spitz MR. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst. 2010;102(15):1199–205.
Etter JF, Hoda JC, Perroud N, Munafo M, Buresi C, Duret C, Neidhart E, Malafosse A, Bertrand D. Association of genes coding for the alpha-4, alpha-5, beta-2 and beta-3 subunits of nicotinic receptors with cigarette smoking and nicotine dependence. Addict Behav. 2009;34(9):772–5.